Board of Directors
(hydroxyprogesterone caproate injection)
(estradiol transdermal spray)
(Butoconazole Nitrate Vaginal Cream USP, 2%)
Ask the Healthcare Professional
Upcoming Investor Events
Board of Directors
Research & Development
Update on Ongoing Makena
5/19/2013 10:51:07 PM
Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing
January 24, 2013
St. Louis, January 24, 2013 – Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHA/KVPHB), and Perrigo Company (Nasdaq: PRGO; TASE) announced today that Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women1, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country.
K-V Pharmaceutical Receives Court Approval of Hologic Settlement
December 28, 2012
St. Louis, MO, December 28, 2012 – K-V Pharmaceutical Company (“K-V” or “the Company”) today announced that the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding, approved the Company’s settlement agreement with Hologic, Inc. (“Hologic Settlement”), and authorized the Company to enter into an $85 million debtor-in-possession (“DIP”) financing to, among other things, fund the settlement.
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
December 12, 2012
ST. LOUIS, Dec. 12, 2012 -- K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession ("DIP") financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"), provide additional financial flexibility during the pendency of the Companys Chapter 11 proceeding and fund certain payments under a proposed reorganization plan. The new DIP financing, the Hologic Settlement and the reorganization plan (and rel1ated disclosure statement) are each subject to approval of the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.
©2013 KV Pharmaceutical Company. All Rights Reserved.